Parallel Closes Two Florida Cannabis Facilities and Lays Off 211 Workers: What It Means for Patients and the Industry

Parallel Closes Florida Cannabis Facilities, Lays Off 211 Workers

One of Florida’s largest medical cannabis operators has permanently closed two cultivation and processing facilities in the Tampa Bay region, eliminating 211 jobs and taking more than 330,000 square feet of operational greenhouse space offline.

Parallel Florida LLC—the corporate parent of Surterra Wellness—reported the layoffs in a Worker Adjustment and Retraining Notification filed with the Florida Department of Commerce. According to Cannabis Business Times, the job cuts occurred during a 14-day period beginning July 6, 2026, and affected facilities in Wimauma and Lakeland.

For the 211 employees and their families, this is not an abstract corporate reorganization. It is a permanent loss of employment. For Florida patients and cannabis advocates, it is also another reminder that a large medical marijuana program does not automatically produce a stable, competitive or worker-friendly cannabis industry.

What happened at Parallel’s Florida cannabis facilities?

Parallel permanently closed facilities located at 2324 W. Lake Drive in Wimauma and 3516 Hamilton Road in Lakeland.

The Wimauma closure affected 157 workers, including 43 production technicians and 27 cultivation technicians. The Lakeland closure affected another 54 workers, including 22 cultivation technicians. The employees were not represented by a union.

The company’s WARN notice stated that both locations would remain permanently closed and that affected workers had received information about Florida’s Rapid Response Program and reemployment resources.

The closures are especially significant for the Tampa Bay area. Wimauma is in Hillsborough County, while Lakeland sits immediately east of the region in Polk County. These were local cannabis jobs—cultivation, production and technical positions—not simply numbers on a national company’s balance sheet.

This does not mean Florida patients stopped using medical cannabis

It would be easy to interpret two major facility closures as evidence of collapsing demand. The available facts point to a more complicated explanation.

At the time of the closures, Florida’s medical marijuana program had more than 937,000 actively registered qualified patients. Surterra continued operating dozens of dispensaries across the state. Just days after the original closure report, Canadian cannabis company SNDL announced that it had completed the acquisition of certain Parallel and Surterra assets through a secured-creditor foreclosure and restructuring.

SNDL’s announcement described the remaining Florida operation as 43 Surterra Wellness dispensaries supplied by a single cultivation and production facility of approximately 175,000 square feet.

In other words, the retail brand did not simply disappear. The business was consolidated around fewer production assets while ownership and debt were restructured. The facilities closed, workers lost their jobs and the surviving operation moved forward under a new financial arrangement.

Parallel’s closures are part of a longer corporate restructuring

Parallel’s recent history helps explain why these shutdowns matter.

The company pursued aggressive expansion during the period when Florida was widely viewed as one of the country’s most attractive limited-license cannabis markets. It entered major real-estate transactions involving the Wimauma and Lakeland properties, attempted a $1.9 billion public-market merger in 2021 and expanded into several states.

That proposed merger was later terminated. Parallel subsequently faced investor litigation, debt pressure and a broader restructuring. In July 2026, SNDL said the asset transaction substantially reduced Parallel’s legacy debt and gave SNDL indirect majority economic exposure to the reorganized operation.

The result is a familiar pattern in the legal cannabis industry: rapid growth, expensive capital, ambitious projections, restructuring and consolidation. Workers and local communities often experience the consequences most directly.

Florida’s vertical integration system raises the stakes

Florida law requires a licensed medical marijuana treatment center, or MMTC, to control the cannabis supply chain from cultivation and processing through transportation and retail dispensing. This is commonly known as vertical integration.

The system may simplify regulatory oversight, but it also requires enormous amounts of capital. A company must finance cultivation infrastructure, manufacturing, compliance, distribution and retail locations instead of specializing in one part of the market.

That structure creates several concerns:

• Large operators have an advantage over smaller or locally owned businesses.

• A financial problem at one company can affect cultivation, manufacturing, retail access and hundreds of workers at once.

• Licenses and operations can become concentrated through mergers, foreclosures and restructurings.

• Patients may have many storefronts to choose from while the underlying market remains controlled by a relatively small group of vertically integrated license holders.

Florida’s own medical marijuana statute requires MMTCs to demonstrate the financial and operational ability to cultivate, process and dispense marijuana. The Parallel closures show why policymakers should examine whether the current structure truly delivers long-term stability, competition and statewide patient access.

What could the closures mean for Florida medical marijuana patients?

Surterra’s dispensaries remain open, and there has been no indication that patients will immediately lose access to the brand. However, consolidating Florida production into one remaining facility deserves public attention.

Patients should watch for changes in product availability, pricing, consistency and strain selection. Regulators should closely monitor whether the remaining cultivation capacity can reliably supply the retail network without compromising quality or access.

Florida has historically restricted routine wholesale transfers between MMTCs, although state law provides a process for transfers connected to harvest failures. That makes internal cultivation capacity particularly important. When a vertically integrated operator closes major production facilities, it cannot necessarily replace that supply through the kind of open wholesale market found in other industries.

No single closure proves that patients will face shortages. It does demonstrate why transparent reporting and regulatory oversight matter.

The 211 laid-off workers must remain at the center of the story

Corporate announcements often describe closures using terms such as efficiency, consolidation or operational discipline. Those phrases should not obscure the human impact.

Two hundred eleven people lost their jobs. Many worked directly with the plants and products that made Florida’s medical marijuana program possible. Cultivation technicians, production technicians and other facility employees are part of the cannabis industry’s foundation, yet workers are frequently the first to absorb the impact of a failed expansion strategy or financial restructuring.

Florida should ensure affected workers can quickly access unemployment assistance, retraining and reemployment services. The cannabis industry should also have a serious conversation about labor standards, worker representation and accountability during ownership changes.

Legalization must mean more than creating valuable licenses and investment opportunities. It should create safe, sustainable jobs and an industry in which workers can build careers without being treated as disposable costs.

What Florida policymakers should learn from these closures

The Parallel facility closures offer several lessons for the future of cannabis policy in Florida:

1. A large patient count does not guarantee a healthy market

Florida has one of the largest medical cannabis patient populations in the United States. Yet market size alone cannot overcome excessive debt, high capital requirements or poor corporate decision-making.

2. More dispensary signs do not necessarily mean more competition

Patients may see many retail locations, but true competition also depends on the number and diversity of businesses controlling cultivation, manufacturing and distribution.

3. Workers deserve consideration during cannabis mergers and restructurings

Regulators reviewing ownership changes should consider employment consequences, operational continuity and the company’s plan for serving patients—not only whether the paperwork satisfies financial and licensing requirements.

4. Florida should reconsider barriers to smaller businesses

A more open licensing structure with opportunities for independent cultivators, processors and retailers could distribute risk and allow more Florida entrepreneurs to participate. Sensible regulation can protect patients without requiring every operator to finance an entire statewide supply chain.

5. Transparency protects patients and the public

Facility closures, ownership changes and reductions in production capacity can affect product access. Patients, employees and local communities deserve timely, understandable information about major changes involving licensed operators.

Florida needs cannabis policy built for patients, workers and communities

The closure of Parallel’s Wimauma and Lakeland facilities is more than a business headline. It is a local labor story, a warning about corporate consolidation and a case study in the weaknesses of Florida’s vertically integrated medical marijuana system.

Surterra’s retail operations may continue under a restructured ownership model, but 211 workers cannot simply be edited out of the story. Neither can the loss of more than 330,000 square feet of cultivation and processing space.

Suncoast NORML supports a legal, regulated cannabis market that puts patients first, protects workers, encourages responsible competition and creates genuine opportunities for Florida businesses. As the state’s cannabis industry changes, lawmakers and regulators must ask a basic question: Is the system serving the public, or is it primarily protecting a small number of highly capitalized license holders?

Florida’s medical cannabis program has grown too large—and matters to too many people—to ignore that question.

Frequently asked questions

Why did Parallel close its Florida cannabis facilities?

Parallel did not provide a detailed public explanation in the WARN notice beyond confirming that the closures and job losses were permanent. The shutdowns occurred amid a broader debt restructuring and acquisition of certain Parallel and Surterra assets by SNDL.

How many Florida cannabis workers were laid off?

A total of 211 employees were affected: 157 at the Wimauma facility and 54 at the Lakeland facility.

How large were the closed facilities?

The two facilities comprised more than 330,000 square feet of operational greenhouse cultivation space, according to reporting based on a 2023 securities filing.

Are Surterra Wellness dispensaries closing in Florida?

The two reported closures involved cultivation and processing facilities, not a statewide shutdown of Surterra retail stores. SNDL reported that 43 Surterra Wellness dispensaries remained part of the acquired Florida operation.

What is vertical integration in Florida’s cannabis market?

Vertical integration means a licensed Florida MMTC is responsible for multiple stages of the supply chain, including cultivation, processing, transportation and dispensing. Critics argue that the model creates high financial barriers and favors large companies over smaller operators.